Tezosentan in the Treatment of Acute Heart Failure
Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
The randomized patients with acute heart failure will be stratified based on the presence or
absence of a Swan-Ganz catheter and assigned to receive either tezosentan 5 mg/h for the
first 30 minutes and 1 mg/h thereafter or matching placebo in a 1:1 manner. The duration of
the treatment is 24 hours up to 72 hours. The duration of the follow-up period is 30 days
after treatment initiation for death, re-hospitalizations and SAEs followed by a follow-up
period of 5 months for vital status.